Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction
Abdominal aortic aneurysm (AAA) is a common disease with as yet unclear cause. Increased matrix metalloproteinase (MMP) levels in the plasma and aorta are a consistent finding in AAA. Although the role of MMPs in AAA has largely been attributed to degradation of the extracellular matrix proteins, th...
Gespeichert in:
Veröffentlicht in: | Journal of vascular surgery 2004-11, Vol.40 (5), p.1001-1010 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1010 |
---|---|
container_issue | 5 |
container_start_page | 1001 |
container_title | Journal of vascular surgery |
container_volume | 40 |
creator | CHEW, David K. W CONTE, Michael S KHALIL, Raouf A |
description | Abdominal aortic aneurysm (AAA) is a common disease with as yet unclear cause. Increased matrix metalloproteinase (MMP) levels in the plasma and aorta are a consistent finding in AAA. Although the role of MMPs in AAA has largely been attributed to degradation of the extracellular matrix proteins, the effects of MMPs on the mechanisms of aortic contraction are unclear. The purpose of this study was to test the hypothesis that MMPs promote aortic dilation by inhibiting the Ca2+ mobilization mechanisms of smooth muscle contraction.
Isometric contraction and 45Ca2+ influx were measured in aortic strips isolated from male Sprague-Dawley rats treated or not treated with MMP-2 and MMP-9.
In normal Krebs solution (2.5 mmol/L Ca2+ ) phenylephrine (10-5 mol/L) caused contraction of the aortic strips, which was significantly inhibited (P < .05) by MMP-2 (maximum, 48.9% +/- 5.0%) and to a greater extent by MMP-9 (maximum, 69.8% +/- 6.2%). The MMP-induced inhibition of phenylephrine contraction depended on concentration and time. The inhibitory effects of MMPs on phenylephrine contraction were reversible. In Ca2+ -free (2 mmol/L ethylene glycol bis[beta-aminoethyl ether]-N,N,N',N'-tetraacetic acid) Krebs solution phenylephrine caused a small contraction that was not inhibited by MMP-2 or MMP-9, which suggests that MMPs do not inhibit Ca2+ release from the intracellular stores. Membrane depolarization with 96 mmol/L of potassium chloride, which stimulates Ca2+ entry from the extracellular space, caused a time-dependent and reversible contraction, which was inhibited by MMP-2 and MMP-9. Histologic studies of MMP-treated tissues stained with hematoxylin-eosin or Verhoeff stain for elastin confirmed the absence of degradation of the extracellular matrix. MMP-2 and MMP-9 also caused significant inhibition of 45Ca2+ influx induced by phenylephrine and potassium chloride.
These data suggest that MMP-2 and MMP-9 promote aortic dilation by inhibiting the Ca2+ entry mechanism of vascular smooth muscle contraction.
Abdominal aortic aneurysm (AAA) is a slow and progressive disease. The late stages of AAA are characterized by degenerative changes in the extracellular matrix and smooth muscle components of the aortic wall. The present study describes novel inhibitory effects of matrix metalloproteinase (MMP) on the Ca2+ entry mechanisms of aortic smooth muscle contraction, even in the absence of extracellular matrix degradation. The MMP-induced inhibition of aortic contraction may f |
doi_str_mv | 10.1016/j.jvs.2004.08.035 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67097114</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67097114</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-3d1181c3cc4207fbb4aa6eec99ae3604a40363de5e3427d694ea4a4b8dac1aaa3</originalsourceid><addsrcrecordid>eNpFkE1Lw0AQhveg2Fr9AV4kF71I4k52k02OUvyCihc9yjLZTOiWfNTdtNh_75YWehqYed6X4WHsBngCHPLHVbLa-iTlXCa8SLjIztiUKwlxloKcsEvvV5wDZIW6YBPIskyVoKbs5wNHZ_-ijkZs22HthpFsj55ivyZjG2si2y9tZUc79NHQRHNMHyLqR7cLGbPE3vrO7w9b9GbToovMEK5o9oErdt5g6-n6OGfs--X5a_4WLz5f3-dPi9iIvBhjUQMUYIQxMuWqqSqJmBOZskQSOZcouchFTRkJmao6LyVhWFZFjQYQUczY_aE3_P-7IT_qznpDbYs9DRuvc8VLBSADCAfQuMF7R41eO9uh22ngeu9Rr3TwqPceNS908Bgyt8fyTdVRfUocJQbg7ggEBdg2Dntj_YnL07IUSol_mQ2AgA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67097114</pqid></control><display><type>article</type><title>Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>CHEW, David K. W ; CONTE, Michael S ; KHALIL, Raouf A</creator><creatorcontrib>CHEW, David K. W ; CONTE, Michael S ; KHALIL, Raouf A</creatorcontrib><description>Abdominal aortic aneurysm (AAA) is a common disease with as yet unclear cause. Increased matrix metalloproteinase (MMP) levels in the plasma and aorta are a consistent finding in AAA. Although the role of MMPs in AAA has largely been attributed to degradation of the extracellular matrix proteins, the effects of MMPs on the mechanisms of aortic contraction are unclear. The purpose of this study was to test the hypothesis that MMPs promote aortic dilation by inhibiting the Ca2+ mobilization mechanisms of smooth muscle contraction.
Isometric contraction and 45Ca2+ influx were measured in aortic strips isolated from male Sprague-Dawley rats treated or not treated with MMP-2 and MMP-9.
In normal Krebs solution (2.5 mmol/L Ca2+ ) phenylephrine (10-5 mol/L) caused contraction of the aortic strips, which was significantly inhibited (P < .05) by MMP-2 (maximum, 48.9% +/- 5.0%) and to a greater extent by MMP-9 (maximum, 69.8% +/- 6.2%). The MMP-induced inhibition of phenylephrine contraction depended on concentration and time. The inhibitory effects of MMPs on phenylephrine contraction were reversible. In Ca2+ -free (2 mmol/L ethylene glycol bis[beta-aminoethyl ether]-N,N,N',N'-tetraacetic acid) Krebs solution phenylephrine caused a small contraction that was not inhibited by MMP-2 or MMP-9, which suggests that MMPs do not inhibit Ca2+ release from the intracellular stores. Membrane depolarization with 96 mmol/L of potassium chloride, which stimulates Ca2+ entry from the extracellular space, caused a time-dependent and reversible contraction, which was inhibited by MMP-2 and MMP-9. Histologic studies of MMP-treated tissues stained with hematoxylin-eosin or Verhoeff stain for elastin confirmed the absence of degradation of the extracellular matrix. MMP-2 and MMP-9 also caused significant inhibition of 45Ca2+ influx induced by phenylephrine and potassium chloride.
These data suggest that MMP-2 and MMP-9 promote aortic dilation by inhibiting the Ca2+ entry mechanism of vascular smooth muscle contraction.
Abdominal aortic aneurysm (AAA) is a slow and progressive disease. The late stages of AAA are characterized by degenerative changes in the extracellular matrix and smooth muscle components of the aortic wall. The present study describes novel inhibitory effects of matrix metalloproteinase (MMP) on the Ca2+ entry mechanisms of aortic smooth muscle contraction, even in the absence of extracellular matrix degradation. The MMP-induced inhibition of aortic contraction may further explain the role of increased MMP activity particularly during the early development of AAA. Chronic exposure to MMPs may lead to protracted inhibition of aortic contraction, progressive aortic dilation, and aneurysm formation. MMP-9 is a more potent inhibitor of aortic contraction than MMP-2, consistent with a more dominant role in AAA. Restoration and preservation of smooth muscle contractile function by specific inhibitors of MMPs may represent a new strategy in preventing the progression of small AAA.</description><identifier>ISSN: 0741-5214</identifier><identifier>DOI: 10.1016/j.jvs.2004.08.035</identifier><identifier>PMID: 15557917</identifier><identifier>CODEN: JVSUES</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animals ; Aorta, Thoracic - drug effects ; Aorta, Thoracic - pathology ; Biological and medical sciences ; Biopsy, Needle ; Blood and lymphatic vessels ; Calcium - metabolism ; Cardiology. Vascular system ; Disease Models, Animal ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Emergency and intensive care: renal failure. Dialysis management ; Immunohistochemistry ; Intensive care medicine ; Male ; Matrix Metalloproteinase 2 - pharmacology ; Matrix Metalloproteinase 9 - pharmacology ; Medical sciences ; Muscle, Smooth, Vascular - drug effects ; Muscle, Smooth, Vascular - physiology ; Probability ; Rats ; Rats, Sprague-Dawley ; Sensitivity and Specificity ; Statistics, Nonparametric ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels ; Vasoconstriction - drug effects ; Vasoconstriction - physiology ; Vasodilation - drug effects ; Vasodilation - physiology</subject><ispartof>Journal of vascular surgery, 2004-11, Vol.40 (5), p.1001-1010</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-3d1181c3cc4207fbb4aa6eec99ae3604a40363de5e3427d694ea4a4b8dac1aaa3</citedby><cites>FETCH-LOGICAL-c368t-3d1181c3cc4207fbb4aa6eec99ae3604a40363de5e3427d694ea4a4b8dac1aaa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16299377$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15557917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHEW, David K. W</creatorcontrib><creatorcontrib>CONTE, Michael S</creatorcontrib><creatorcontrib>KHALIL, Raouf A</creatorcontrib><title>Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction</title><title>Journal of vascular surgery</title><addtitle>J Vasc Surg</addtitle><description>Abdominal aortic aneurysm (AAA) is a common disease with as yet unclear cause. Increased matrix metalloproteinase (MMP) levels in the plasma and aorta are a consistent finding in AAA. Although the role of MMPs in AAA has largely been attributed to degradation of the extracellular matrix proteins, the effects of MMPs on the mechanisms of aortic contraction are unclear. The purpose of this study was to test the hypothesis that MMPs promote aortic dilation by inhibiting the Ca2+ mobilization mechanisms of smooth muscle contraction.
Isometric contraction and 45Ca2+ influx were measured in aortic strips isolated from male Sprague-Dawley rats treated or not treated with MMP-2 and MMP-9.
In normal Krebs solution (2.5 mmol/L Ca2+ ) phenylephrine (10-5 mol/L) caused contraction of the aortic strips, which was significantly inhibited (P < .05) by MMP-2 (maximum, 48.9% +/- 5.0%) and to a greater extent by MMP-9 (maximum, 69.8% +/- 6.2%). The MMP-induced inhibition of phenylephrine contraction depended on concentration and time. The inhibitory effects of MMPs on phenylephrine contraction were reversible. In Ca2+ -free (2 mmol/L ethylene glycol bis[beta-aminoethyl ether]-N,N,N',N'-tetraacetic acid) Krebs solution phenylephrine caused a small contraction that was not inhibited by MMP-2 or MMP-9, which suggests that MMPs do not inhibit Ca2+ release from the intracellular stores. Membrane depolarization with 96 mmol/L of potassium chloride, which stimulates Ca2+ entry from the extracellular space, caused a time-dependent and reversible contraction, which was inhibited by MMP-2 and MMP-9. Histologic studies of MMP-treated tissues stained with hematoxylin-eosin or Verhoeff stain for elastin confirmed the absence of degradation of the extracellular matrix. MMP-2 and MMP-9 also caused significant inhibition of 45Ca2+ influx induced by phenylephrine and potassium chloride.
These data suggest that MMP-2 and MMP-9 promote aortic dilation by inhibiting the Ca2+ entry mechanism of vascular smooth muscle contraction.
Abdominal aortic aneurysm (AAA) is a slow and progressive disease. The late stages of AAA are characterized by degenerative changes in the extracellular matrix and smooth muscle components of the aortic wall. The present study describes novel inhibitory effects of matrix metalloproteinase (MMP) on the Ca2+ entry mechanisms of aortic smooth muscle contraction, even in the absence of extracellular matrix degradation. The MMP-induced inhibition of aortic contraction may further explain the role of increased MMP activity particularly during the early development of AAA. Chronic exposure to MMPs may lead to protracted inhibition of aortic contraction, progressive aortic dilation, and aneurysm formation. MMP-9 is a more potent inhibitor of aortic contraction than MMP-2, consistent with a more dominant role in AAA. Restoration and preservation of smooth muscle contractile function by specific inhibitors of MMPs may represent a new strategy in preventing the progression of small AAA.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animals</subject><subject>Aorta, Thoracic - drug effects</subject><subject>Aorta, Thoracic - pathology</subject><subject>Biological and medical sciences</subject><subject>Biopsy, Needle</subject><subject>Blood and lymphatic vessels</subject><subject>Calcium - metabolism</subject><subject>Cardiology. Vascular system</subject><subject>Disease Models, Animal</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Immunohistochemistry</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Matrix Metalloproteinase 2 - pharmacology</subject><subject>Matrix Metalloproteinase 9 - pharmacology</subject><subject>Medical sciences</subject><subject>Muscle, Smooth, Vascular - drug effects</subject><subject>Muscle, Smooth, Vascular - physiology</subject><subject>Probability</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Sensitivity and Specificity</subject><subject>Statistics, Nonparametric</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels</subject><subject>Vasoconstriction - drug effects</subject><subject>Vasoconstriction - physiology</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilation - physiology</subject><issn>0741-5214</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1Lw0AQhveg2Fr9AV4kF71I4k52k02OUvyCihc9yjLZTOiWfNTdtNh_75YWehqYed6X4WHsBngCHPLHVbLa-iTlXCa8SLjIztiUKwlxloKcsEvvV5wDZIW6YBPIskyVoKbs5wNHZ_-ijkZs22HthpFsj55ivyZjG2si2y9tZUc79NHQRHNMHyLqR7cLGbPE3vrO7w9b9GbToovMEK5o9oErdt5g6-n6OGfs--X5a_4WLz5f3-dPi9iIvBhjUQMUYIQxMuWqqSqJmBOZskQSOZcouchFTRkJmao6LyVhWFZFjQYQUczY_aE3_P-7IT_qznpDbYs9DRuvc8VLBSADCAfQuMF7R41eO9uh22ngeu9Rr3TwqPceNS908Bgyt8fyTdVRfUocJQbg7ggEBdg2Dntj_YnL07IUSol_mQ2AgA</recordid><startdate>20041101</startdate><enddate>20041101</enddate><creator>CHEW, David K. W</creator><creator>CONTE, Michael S</creator><creator>KHALIL, Raouf A</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041101</creationdate><title>Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction</title><author>CHEW, David K. W ; CONTE, Michael S ; KHALIL, Raouf A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-3d1181c3cc4207fbb4aa6eec99ae3604a40363de5e3427d694ea4a4b8dac1aaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animals</topic><topic>Aorta, Thoracic - drug effects</topic><topic>Aorta, Thoracic - pathology</topic><topic>Biological and medical sciences</topic><topic>Biopsy, Needle</topic><topic>Blood and lymphatic vessels</topic><topic>Calcium - metabolism</topic><topic>Cardiology. Vascular system</topic><topic>Disease Models, Animal</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Immunohistochemistry</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Matrix Metalloproteinase 2 - pharmacology</topic><topic>Matrix Metalloproteinase 9 - pharmacology</topic><topic>Medical sciences</topic><topic>Muscle, Smooth, Vascular - drug effects</topic><topic>Muscle, Smooth, Vascular - physiology</topic><topic>Probability</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Sensitivity and Specificity</topic><topic>Statistics, Nonparametric</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels</topic><topic>Vasoconstriction - drug effects</topic><topic>Vasoconstriction - physiology</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilation - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHEW, David K. W</creatorcontrib><creatorcontrib>CONTE, Michael S</creatorcontrib><creatorcontrib>KHALIL, Raouf A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of vascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHEW, David K. W</au><au>CONTE, Michael S</au><au>KHALIL, Raouf A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction</atitle><jtitle>Journal of vascular surgery</jtitle><addtitle>J Vasc Surg</addtitle><date>2004-11-01</date><risdate>2004</risdate><volume>40</volume><issue>5</issue><spage>1001</spage><epage>1010</epage><pages>1001-1010</pages><issn>0741-5214</issn><coden>JVSUES</coden><abstract>Abdominal aortic aneurysm (AAA) is a common disease with as yet unclear cause. Increased matrix metalloproteinase (MMP) levels in the plasma and aorta are a consistent finding in AAA. Although the role of MMPs in AAA has largely been attributed to degradation of the extracellular matrix proteins, the effects of MMPs on the mechanisms of aortic contraction are unclear. The purpose of this study was to test the hypothesis that MMPs promote aortic dilation by inhibiting the Ca2+ mobilization mechanisms of smooth muscle contraction.
Isometric contraction and 45Ca2+ influx were measured in aortic strips isolated from male Sprague-Dawley rats treated or not treated with MMP-2 and MMP-9.
In normal Krebs solution (2.5 mmol/L Ca2+ ) phenylephrine (10-5 mol/L) caused contraction of the aortic strips, which was significantly inhibited (P < .05) by MMP-2 (maximum, 48.9% +/- 5.0%) and to a greater extent by MMP-9 (maximum, 69.8% +/- 6.2%). The MMP-induced inhibition of phenylephrine contraction depended on concentration and time. The inhibitory effects of MMPs on phenylephrine contraction were reversible. In Ca2+ -free (2 mmol/L ethylene glycol bis[beta-aminoethyl ether]-N,N,N',N'-tetraacetic acid) Krebs solution phenylephrine caused a small contraction that was not inhibited by MMP-2 or MMP-9, which suggests that MMPs do not inhibit Ca2+ release from the intracellular stores. Membrane depolarization with 96 mmol/L of potassium chloride, which stimulates Ca2+ entry from the extracellular space, caused a time-dependent and reversible contraction, which was inhibited by MMP-2 and MMP-9. Histologic studies of MMP-treated tissues stained with hematoxylin-eosin or Verhoeff stain for elastin confirmed the absence of degradation of the extracellular matrix. MMP-2 and MMP-9 also caused significant inhibition of 45Ca2+ influx induced by phenylephrine and potassium chloride.
These data suggest that MMP-2 and MMP-9 promote aortic dilation by inhibiting the Ca2+ entry mechanism of vascular smooth muscle contraction.
Abdominal aortic aneurysm (AAA) is a slow and progressive disease. The late stages of AAA are characterized by degenerative changes in the extracellular matrix and smooth muscle components of the aortic wall. The present study describes novel inhibitory effects of matrix metalloproteinase (MMP) on the Ca2+ entry mechanisms of aortic smooth muscle contraction, even in the absence of extracellular matrix degradation. The MMP-induced inhibition of aortic contraction may further explain the role of increased MMP activity particularly during the early development of AAA. Chronic exposure to MMPs may lead to protracted inhibition of aortic contraction, progressive aortic dilation, and aneurysm formation. MMP-9 is a more potent inhibitor of aortic contraction than MMP-2, consistent with a more dominant role in AAA. Restoration and preservation of smooth muscle contractile function by specific inhibitors of MMPs may represent a new strategy in preventing the progression of small AAA.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>15557917</pmid><doi>10.1016/j.jvs.2004.08.035</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0741-5214 |
ispartof | Journal of vascular surgery, 2004-11, Vol.40 (5), p.1001-1010 |
issn | 0741-5214 |
language | eng |
recordid | cdi_proquest_miscellaneous_67097114 |
source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Animals Aorta, Thoracic - drug effects Aorta, Thoracic - pathology Biological and medical sciences Biopsy, Needle Blood and lymphatic vessels Calcium - metabolism Cardiology. Vascular system Disease Models, Animal Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Emergency and intensive care: renal failure. Dialysis management Immunohistochemistry Intensive care medicine Male Matrix Metalloproteinase 2 - pharmacology Matrix Metalloproteinase 9 - pharmacology Medical sciences Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - physiology Probability Rats Rats, Sprague-Dawley Sensitivity and Specificity Statistics, Nonparametric Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels Vasoconstriction - drug effects Vasoconstriction - physiology Vasodilation - drug effects Vasodilation - physiology |
title | Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T11%3A16%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Matrix%20metalloproteinase-specific%20inhibition%20of%20Ca2+%20entry%20mechanisms%20of%20vascular%20contraction&rft.jtitle=Journal%20of%20vascular%20surgery&rft.au=CHEW,%20David%20K.%20W&rft.date=2004-11-01&rft.volume=40&rft.issue=5&rft.spage=1001&rft.epage=1010&rft.pages=1001-1010&rft.issn=0741-5214&rft.coden=JVSUES&rft_id=info:doi/10.1016/j.jvs.2004.08.035&rft_dat=%3Cproquest_cross%3E67097114%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67097114&rft_id=info:pmid/15557917&rfr_iscdi=true |